|
ZNF302 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.28119770137891E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.68119987218074E-10 |
| Normal-vs-Stage2 |
1.13050000472015E-08 |
| Normal-vs-Stage3 |
1.41775480244632E-13 |
| Normal-vs-Stage4 |
8.27879986786684E-10 |
| Stage1-vs-Stage2 |
7.834800E-01 |
| Stage1-vs-Stage3 |
5.319700E-02 |
| Stage1-vs-Stage4 |
7.335700E-02 |
| Stage2-vs-Stage3 |
3.001000E-01 |
| Stage2-vs-Stage4 |
2.654600E-01 |
| Stage3-vs-Stage4 |
7.736200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.27370353048195E-11 |
| Normal-vs-AfricanAmerican |
9.97630000054706E-07 |
| Normal-vs-Asian |
3.83790000000328E-05 |
| Caucasian-vs-AfricanAmerican |
6.809600E-01 |
| Caucasian-vs-Asian |
1.500070E-02 |
| AfricanAmerican-vs-Asian |
6.551700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.86120049664396E-11 |
| Normal-vs-Female |
2.45280462607411E-11 |
| Male-vs-Female |
1.600190E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.75329972762484E-10 |
| Normal-vs-Age(41-60Yrs) |
1.79089965079982E-10 |
| Normal-vs-Age(61-80Yrs) |
2.03249639341152E-11 |
| Normal-vs-Age(81-100Yrs) |
5.939400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.981400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.764600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.580600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.580600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.577000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.142400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.84260000000758E-05 |
| Classical-VS-Follicular |
9.906400E-01 |
| Classical-VS-Other |
6.059400E-01 |
| Classical-VS-Normal |
2.32170005443066E-09 |
| Tall-VS-Follicular |
7.552600E-04 |
| Tall-VS-Other |
1.620090E-02 |
| Tall-VS-Normal |
1.82898141076748E-12 |
| Follicular-VS-Other |
6.317200E-01 |
| Follicular-VS-Normal |
1.48279999390155E-09 |
| Other-VS-Normal |
3.013800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.68753899743024E-14 |
| Normal-vs-N1 |
1.26520000032215E-07 |
| N0-vs-N1 |
9.174800E-01 |
|
|
